Q
Quince Therapeutics, Inc. (QNCX)
NMS – Real vaqt narxi. Valyuta: USD
0.94
-0.03 (-3.34%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.96
+0.02 (1.63%)
Bozordan keyin: Jun 26, 2026, 7:56 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
0.94
-0.03 (-3.34%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.96
+0.02 (1.63%)
Bozordan keyin: Jun 26, 2026, 7:56 PM EDT
Quince Therapeutics, Inc., biotexnologiya kompaniyasi, nogironlik va kam uchraydigan kasalliklarga chalingan bemorlar uchun terapevtik vositalarni sotib olish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning asosiy dori nomzodi eDSP bo'lib, u kam uchraydigan pediatrik neyrodegenerativ kasalliklarni, shu jumladan ATM genidagi mutatsiyalar tufayli kelib chiqqan irsiy autosomal resessiv neyrodegenerativ va immunitet tanqisligi buzilishi bo'lgan A-Tni davolash uchun 3-bosqichda. Uning AIDE texnologik platformasi, dori/jihoz kombinatsiyasi platformasi bo'lib, u dori vositasini bemorning o'z eritrotsitlariga kapsulalash uchun avtomatlashtirilgan jarayonni qo'llaydi, shuningdek, RCL avtomatlashtirilgan uskunalaridan, tibbiy jihozlar, shprits to'plami va jarayon eritmalarini o'z ichiga olgan steril bir martalik sarflanadigan davolash to'plamidan iborat. Kompaniya ilgari Cortexyme, Inc. nomi bilan tanilgan va 2022 yil avgust oyida Quince Therapeutics, Inc. nomini o'zgartirgan. Kompaniya 2012 yilda tashkil etilgan va Kaliforniyaning Janubiy San-Frantsisko shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charles S. Ryan J.D., Ph.D. | President |
| Dr. Dirk Thye M.D. | CEO, Chief Medical Officer & Director |
| Mr. Brendan Hannah M.B.A. | Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 8-K | d168420d8k.htm |
| 2026-06-11 | 8-K | d124733d8k.htm |
| 2026-05-21 | 8-K | d139014d8k.htm |
| 2026-05-18 | 8-K/A | d135388d8ka.htm |
| 2026-05-18 | 8-K | d109149d8k.htm |
| 2026-05-11 | 10-Q | qncx-20260331.htm |
| 2026-04-28 | 8-K | d623526d8k.htm |
| 2026-04-27 | DEFA14A | qncx-20260424.htm |
| 2026-04-27 | DEF 14A | qncx-20260424.htm |
| 2026-04-27 | ARS | qncx-ars-fy2025.pdf |